文献速递类风湿关节炎

质子泵抑制剂或瑞巴派特使用对类风湿关节炎患者肠道菌群的影响

Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究比较了15名健康对照和32名接受质子泵抑制剂(PPI)、H2受体拮抗剂或瑞巴派特的类风湿关节炎(RA)患者的粪便菌群16S rRNA测序结果。RA患者肠道菌群多样性降低且组成改变;接受PPI者的菌群与接受瑞巴派特者显著不同(P=0.005),PPI组链球菌富集且毒力因子相关功能通路增多,提示不适当PPI使用可能对RA患者有害。

要点

  • RA患者肠道菌群多样性降低且组成改变。
  • PPI使用者与瑞巴派特使用者肠道菌群显著不同(P=0.005)。
  • PPI组链球菌富集且毒力因子功能通路增多。

核心结论

  • 接受PPI的RA患者肠道菌群与接受瑞巴派特者不同,PPI组富集的毒力功能提示不适当PPI使用可能对RA患者有害。

研究设计与样本

  • 研究纳入15名健康对照和32名接受PPI、H2受体拮抗剂或瑞巴派特的RA患者,采集粪便样本进行16S rRNA测序,并使用QIIME和PICRUSt分析菌群组成与功能。

主要发现

  • 与健康对照相比,RA患者肠道菌群多样性降低且组成改变。
  • 接受抑酸药物(尤其是PPI)的RA患者肠道菌群与接受瑞巴派特者不同(PPI vs 瑞巴派特,P=0.005)。
  • PPI组链球菌富集,瑞巴派特组Clostridium bolteae富集。
  • PPI使用者肠道菌群中毒力因子产生相关功能通路丰富,且该功能与链球菌相对丰度正相关。

临床怎么用

  • RA患者使用PPI时应评估必要性,避免不适当使用,因其可能与肠道菌群毒力功能富集相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with RA commonly use gastrointestinal (GI) protective drugs for treatment and prevention of drug-associated GI injuries. However, how these drugs affect the gut microbiota in RA patients remains unknown. The objective of this study was to examine the gut microbiota of RA patients according to use of GI protective drugs such as proton pump inhibitors (PPIs), histamine 2-receptor antagonists and rebamipide. METHODS: Faecal samples were obtained from 15 healthy controls and 32 RA patients who were receiving PPI, histamine 2-receptor antagonist or rebamipide. Bacterial DNA was extracted from the faecal samples and 16S rRNA sequencing was performed. Microbial composition and function were analysed using Quantitative Insights Into Microbial Ecology and Phylogenetic Investigation of Communities by Reconstruction of Unobserved States. RESULTS: RA patients exhibited reduced diversity and altered composition of the gut microbiota compared with healthy controls. The gut microbiota of RA patients receiving acid-suppressing drugs, particularly PPIs, was distinct from that of RA patients receiving rebamipide (PPI vs rebamipide, P = 0.005). Streptococcus was enriched in RA patients receiving PPI, while Clostridium bolteae was enriched in RA patients receiving rebamipide. The gut microbiota of PPI users was abundant with microbial functional pathway involved in the production of virulence factors. This featured microbial function was positively correlated with relative abundance of Streptococcus, the differentially abundant taxa of PPI users. CONCLUSION: The gut microbiota of RA patients receiving PPIs was distinguishable from that of those receiving rebamipide. The enriched virulent function in the gut microbiota of PPI users suggests that inappropriate PPI use may be harmful in RA patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kim JW, Jeong Y, Park SJ, et al. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients. Rheumatology (Oxford). 2021. PMID: 32789440. doi:10.1093/rheumatology/keaa316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。